Search Results - "NGAI, ANGELA"

Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy by Maertens, Johan, Raad, Issam, Petrikkos, George, Boogaerts, Marc, Selleslag, Dominik, Petersen, Finn B., Sable, Carole A., Kartsonis, Nicholas A., Ngai, Angela, Taylor, Arlene, Patterson, Thomas F., Denning, David W., Walsh, Thomas J.

“…Background. Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients. Echinocandins are novel antifungal…”
Get full text

Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants by Marshall, Gary S, Adams, Gregory L, Leonardi, Michael L, Petrecz, Maria, Flores, Sheryl A, Ngai, Angela L, Xu, Jin, Liu, Guanghan, Stek, Jon E, Foglia, Ginamarie, Lee, Andrew W

“…DTaP5-IPV-Hib-HepB is a fully liquid investigational hexavalent vaccine directed against 6 diseases. This multicenter, open-label, comparator-controlled, phase…”
Get full text

Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non-albicans Candida Species: Review of the Caspofungin Database by COLOMBO, Arnaldo L, NGAI, Angela L, BOURQUE, Michael, BRADSHAW, Susan K, STROHMAIER, Kim M, TAYLOR, Arlene F, LUPINACCI, Robert J, KARTSONIS, Nicholas A

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients by LI, Chi-Chung, PENG SUN, YINGWEN DONG, SHENG BI, DESAI, Rajesh, FALLON DOCKENDORF, Marissa, KARTSONIS, Nicholas A, NGAI, Angela L, BRADSHAW, Susan, STONE, Julie A

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients by Zaoutis, Theoklis E, Jafri, Hasan S, Huang, Li-Min, Locatelli, Franco, Barzilai, Asher, Ebell, Wolfram, Steinbach, William J, Bradley, John, Lieberman, Jay M, Hsiao, Chih-Cheng, Seibel, Nita, Laws, Hans-Juergen, Gamba, Melinda, Petrecz, Maria, Taylor, Arlene F, Strohmaier, Kim M, Chow, Joseph W, Kartsonis, Nicholas A, Ngai, Angela L

“…We evaluated the safety, tolerability, and efficacy of caspofungin in pediatric patients with invasive aspergillosis, invasive candidiasis, or esophageal…”
Get full text

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report by Ngai, Angela L, Bourque, Michael R, Lupinacci, Robert J, Strohmaier, Kim M, Kartsonis, Nicholas A

“…Abstract Safety experience is available from 32 completed clinical studies (17 Phase I and 15 Phase II–III) of caspofungin (CAS) conducted between 1995 and…”
Get full text

SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS by ZAOUTIS, Theoklis, LEHRNBECHER, Thomas, BOURQUE, Michael, BRADSHAW, Susan K, PETRECZ, Maria, KARTSONIS, Nicholas A, GROLL, Andreas H, STEINBACH, William J, JAFRI, Hasan S, MAERTENS, Johan, NGAI, Angela L, CHOW, Joseph W, TAYLOR, Arlene F, STROHMAIER, Kim M

“…We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was…”
Get full text

Measles, Mumps, Rubella, and Varicella Combination Vaccine: Safety and Immunogenicity Alone and in Combination with Other Vaccines Given to Children by White, C. Jo, Stinson, Diane, Staehle, Brenda, Cho, Iksung, Matthews, Holly, Ngai, Angela, Keller, Paul, Eiden, Joseph, Kuter, Barbara

“…Eight hundred and twelve children, 12 months to 3.5 years of age, were enrolled in two clinical studies to evaluate the safety and immunogenicity of a live,…”
Get full text

Dose Titration Study of Live Attenuated Varicella Vaccine in Healthy Children by Rothstein, Edward P., Bernstein, Henry H., Ngai, Angela L., Cho, Iksung, White, C. Jo

“…To approximate the effect of prolonged storage on safety and immunogenicity, healthy children were given a single dose of the currently marketed live…”
Get full text

Evaluation of Serum Sandwich Enzyme-Linked Immunosorbent Assay for Circulating Galactomannan during Caspofungin Therapy: Results from the Caspofungin Invasive Aspergillosis Study by Maertens, Johan, Glasmacher, Axel, Selleslag, Dominik, Ngai, Angela, Ryan, Desmond, Layton, Melissa, Taylor, Arlene, Sable, Carole, Kartsonis, Nicholas

“…There has been minimal clinical experience with the use of the Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) for patients receiving…”
Get full text

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants by Marshall, Gary S., Adams, Gregory, Leonardi, Michael, Petrecz, Maria, Flores, Sheryl, Ngai, Angela, Xu, Jin, Foglia, Ginamarie, Lee, Andrew Wen-Tseng

Get full text

Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis by Comisar, Wendy, Sun, Peng, Li, Susan, Sable, Carole, Schwartz, Michael, Bi, Sheng, Chow, Joseph, Ngai, Angela, Winchell, Gregory, Kartsonis, Nicholas, Stone, Julie

“…Caspofungin is an echinocandin antifungal agent administered once daily as an intravenous infusion. Relationships between caspofungin exposure and clinical…”
Get full text

A web-based endpoint adjudication system for interim analyses in clinical trials by Nolen, Tracy L, Dimmick, Bill F, Ostrosky-Zeichner, Luis, Kendrick, Amy S, Sable, Carole, Ngai, Angela, Wallace, Dennis

“…Background A data monitoring committee (DMC) is often employed to assess trial progress and review safety data and efficacy endpoints throughout a trail…”
Get full text

Evaluation of Serum Sandwich Enzyme-Linked Immunosorbent Assay for Circulating Galactomannan during Caspofungin Therapy: Results from the Caspofungin Invasive Aspergillosis Study [Abstract] by Johan Maertens, Axel Glasmacher, Dominik Selleslag, Angela Ngai, Ryan, Desmond, Melissa Layton, Arlene Taylor, Carole Sable, Nicholas Kartsonis

Get full text

Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine by BERNSTEIN, H. H, ROTHSTEIN, E. P, WATSON, B. M, REISINGER, K. S, BLATTER, M. M, WELLMAN, C. O, CHARTRAND, S. A, CHO, I, NGAI, A, WHITE, C. J

“…To prospectively characterize varicella occurring in children previously immunized with a live attenuated varicella vaccine (breakthrough varicella) through…”
Get full text

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response by White, C J, Kuter, B J, Ngai, A, Hildebrand, C S, Isganitis, K L, Patterson, C M, Capra, A, Miller, W J, Krah, D L, Provost, P J

“…Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine…”
Get more information

Safety and Cellular and Humoral Immune Responses of a Booster Dose of Varicella Vaccine 6 Years after Primary Immunization by Watson, Barbara, Rothstein, Edward, Bernstein, Henry, Arbeter, Allan, Arvin, Ann, Chartrand, Stephen, Clements, Dennis, Kumar, Mary Lou, Reisinger, Keith, Blatter, Mark, Starr, Stuart E., Staehle, Brenda, Ngai, Angela, White, C. Jo

“…Four hundred nineteen children and adolescents immunized with live varicella vaccine 4–6 years earlier were enrolled in a study to evaluate the safety and…”
Get full text

Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children by NGAI, A. L, STAEHLE, B. O, KUTER, B. J, CYANOVICH, N. M, IKSUNG CHO, MATTHEWS, H, KELLER, P, ARVIN, A. M, WATSON, B, WHITE, C. J

“…To compare the safety and immunogenicity of a one- vs. two-dose regimen of Oka/Merck varicella vaccine in approximately 2000 healthy children 12 months to 12…”
Get full text

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax ®) in healthy adolescents and adults by Kuter, Barbara J., Ngai, Angela, Patterson, Carolyn M., Staehle, Brenda O., Cho, Iksung, Matthews, Holly, Provost, Philip J., Jo White, C., the Oka/Merck Varicella Vaccine Study Group

“…A multicenter clinical trial was conducted among 757 healthy adolescents and adults, 13–54 years, to compare two regimens of Oka/Merck varicella vaccine with…”
Get full text

Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R®II, VARIVAX® and TETRAMUNE® in healthy children vs. concomitant injections of M-M-R®II and TETRAMUNE® followed six weeks later by VARIVAX by SHINEFIELD, HENRY R, BLACK, STEVEN B, STAEHLE, BRENDA O, ADELMAN, TAMA, ENSOR, KATHLEEN, NGAI, ANGELA, WHITE, C JO, BIRD, STEVEN R, MATTHEWS, HOLLY, KUTER, BARBARA J

“…OBJECTIVES AND STUDY DESIGN.The primary objectives of this study were to compare immunologic responses, antibody persistence, safety and varicella breakthrough…”
Get full text